Genmab — Marts 2021
-
New trial - Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS) https://clinicaltrials.gov/ct2/show/NCT04788615
-
innovaTV 207 extended, 3rd dosing arm added, enrollment from 250 to 392 https://clinicaltrials.gov/ct2/history/NCT03485209?A=35&B=36&C=merged#StudyPageTop
-
16:10 nope
-
Omkring dagens udvikling - så ser det ud til, at GEN faktisk ikke kørte enegang. Prøv at lægge kursudviklingen på MOR (den tyske notering) ovenpå udviklingen af GEN (den danske notering). De havde præcist samme hug, på præcist samme tidspunkt
-
God morgen.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind